IMMUTEP Ltd
Close on Oct 19, 2026
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Immutep has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Immutep filed with the SEC
Immutep Regains Compliance with Nasdaq Minimum Bid Price Requirement
EX-99.1 to Form 6-K
Change to American Depositary Share Ratio
EX-99.1 to Form 6-K
Immutep Outlines Focused Development Strategy
EX-99.1 to Form 6-K
Year ended 30 June 2026
EX-99.1 to Form 6-K
Immutep Quarterly Activities Report & Appendix 4C Q4 FY26
EX-99.1 to Form 6-K
Immutep Provides Clinical Update in 1 st line NSCLC:
EX-99.1 to Form 6-K
Immutep Quarterly Activities Report & Appendix 4C Q3 FY26
EX-99.1 to Form 6-K
Immutep Receives Nasdaq Notice of Bid Price Deficiency
EX-99.1 to Form 6-K
Immutep Receives FDA Orphan Drug Designation for
EX-99.1 to Form 6-K
Immutep Reports Progress from Phase I Study of LAG-3 Agonist for
EX-99.1 to Form 6-K
TACTI-004 Phase III Study in First Line NSCLC to be discontinued
EX-99.1 to Form 6-K
(previous corresponding period: half-year ended 31 December 2024)
EX-99.1 to Form 6-K
Immutep Quarterly Activities Report & Appendix 4C Q2 FY26
EX-99.1 to Form 6-K
Immutep Announces Positive Update on IMP761, a
EX-99.1 to Form 6-K
Immutep Announces Strong Operational Progress in Global TACTI-004
EX-99.1 to Form 6-K
Immutep to Present New Data from AIPAC-003 Phase II at
EX-99.1 to Form 6-K
Translational Data and Significant Pathologic Response Rates from
EX-99.1 to Form 6-K
Receives A$4.6 million R&D Tax Incentive from French Government
EX-99.1 to Form 6-K
Quarterly Activities Report & Appendix 4C Q1 FY26
EX-99.1 to Form 6-K
Two Posters at ESMO Congress 2025 Highlight Immutep’s Focus on
EX-99.1 to Form 6-K
Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant
EX-99.1 to Form 6-K
Immutep Announces Successful Completion of FDA Project Optimus Requirements
EX-99.1 to Form 6-K
Immutep Announces Update for TACTI-004 (KEYNOTE-F91)
EX-99.1 to Form 6-K
Immutep Announces Research Collaboration with the George
EX-99.1 to Form 6-K
Year ended 30 June 2025
EX-99.1 to Form 6-K
Immutep Quarterly Activities Report & Appendix 4C
EX-99.1 to Form 6-K
Immutep Announces Positive Update from Phase I Study of IMP761,
EX-99.1 to Form 6-K
Immuteps Efti with Radiotherapy &
EX-99.1 to Form 6-K
Immuteps Efti with KEYTRUDA ® (pembrolizumab) & Chemotherapy
EX-99.1 to Form 6-K
Immuteps Efti in Combination with KEYTRUDA ® (pembrolizumab) Drives
EX-99.1 to Form 6-K
Activities Report & Appendix 4C
EX-99.1 to Form 6-K
First Patient Dosed in Immuteps TACTI-004 Phase III Trial
EX-99.1 to Form 6-K
corresponding period: half-year ended 31 December 2023)
EX-99.1 to Form 6-K
Immutep Quarterly Activities Report & Appendix 4C
EX-99.1 to Form 6-K
Immutep Reports Promising New Data in Head and Neck Cancer
EX-99.1 to Form 6-K